glp-1 dual agonist GIPR/GLP-1R therapies for diabetes and weight loss– Chemistry, Physiology and Clinical application Mechanisms of action of GLP-1

Tirzepatide is a dual GLP-1/GIP receptor agonist that has shown even greater weight loss in clinical trialsaveraging 22.5% of body weight over 72 weeks

They stimulate insulin secretion and inhibit glucagon secretion by elevating endogenous GLP-1 concentrations without an intrinsic hypoglycaemia risk

GLP-1 receptor agonists and cardiovascular outcome trials: An update

Cardiovascular disease: risk assessment and reduction, including lipid modification

If you seek permanent results, surgery remains the gold standard

### About the National Consumers League (NCL) The National Consumers League, founded in 1899, is Americas pioneer consumer organization